Global Risk Assessment to Guide Blood Pressure Management in Cardiovascular Disease Prevention
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
E levated blood pressure (BP) is a causal risk factor for cardiovascular disease (CVD).Epidemiological analyses have established the graded and continuous association between higher BP and CVD.Moreover, randomized clinical trials among individuals with hypertension have demonstrated, in aggregate, a reduction in CVD events by 20%, coronary heart disease (CHD) by 17%, stroke by 27%, and heart failure by 28% for every 10 mm Hg systolic BP (SBP) lowering with medical therapy. 1 Therefore, prevention, detection, treatment, and control of elevated BP, and its clinical correlate hypertension, is an important public health priority and a primary target for CVD prevention.Although national health surveys have demonstrated improvements in hypertension awareness and treatment, strategic opportunities to improve the efficiency and efficacy of applying BP-lowering therapy in patients most likely to benefit remain. 2 Global CVD risk assessment, using multivariable prediction models that estimate absolute CVD risk from routinely measured clinical variables, has been promulgated in several CVD prevention guidelines for cholesterol management to target the most intensive preventive therapies to those at highest absolute CVD risk.[3][4][5] Hypertension guidelines, however, have instead relied solely on isolated BP thresholds and BP goals to guide treatment initiation and intensity.In this review, we provide a rationale for incorporating global CVD risk assessment in BP treatment decision-making and propose a framework to guide its implementation in future CVD prevention guidelines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw106 · Cited by 6,457
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
A New Initiative on Precision Medicine
Collins, F. S., & Varmus, H. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500523 · Cited by 5,202
Lloyd-Jones, D. M., Hong, Y., Labarthe, D., Mozaffarian, D., Appel, L. J., Van Horn, L., Greenlund, K., Daniels, S., Nichol, G., Tomaselli, G. F., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.192703 · Cited by 4,750
Self-citationEttehad, D., Emdin, C. A., Kiran, A., Anderson, S. G., Callender, T., Emberson, J., Chalmers, J., Rodgers, A., & Rahimi, K. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01225-8 · Cited by 3,755 · cited 1×
“Moreover, randomized clinical trials among individuals with hypertension have demonstrated, in aggregate, a reduction in CVD events by 20%, coronary heart disease (CHD) by 17%, stroke by 27%, and heart failure by 28% for every 10 mm Hg systolic BP (SBP) lowering with medical therapy.(1) Therefore, prevention, detectio…”
O'Donnell, M. J., Xavier, D., Liu, L., Zhang, H., Chin, S. L., Rao-Melacini, P., Rangarajan, S., Islam, S., Pais, P., McQueen, M. J., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60834-3 · Cited by 3,448
Collaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833
Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age
Lloyd-Jones, D. M., Leip, E. P., Larson, M. G., D’Agostino, R. B., Beiser, A., Wilson, P. W. F., Wolf, P. A., & Levy, D. (2006) · Circulation · doi:10.1161/circulationaha.105.548206 · Cited by 1,298 · cited 1×
“Long-term follow-up from epidemiological studies have consistently shown that many young and middle-aged adults with SBP levels ≥160 mm Hg may have low short-term CVD risk because of their younger age but high lifetime CVD risk during ≥20 years of follow-up.(45,46) Such an observation provides guidance for a potential…”
Self-citationBiomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations
Vasan, R. S. (2006) · Circulation · doi:10.1161/circulationaha.104.482570 · Cited by 1,212
Neaton, J. D. (1992) · Archives of Internal Medicine · doi:10.1001/archinte.1992.00400130082009 · Cited by 784 · cited 6×
“Excess ASCVD events are calculated as the difference between observed and expected ASCVD events, using the ASCVD event rate in the group with untreated SBP 120 mm Hg as the reference (Expected in stratum, n in stratum×event rate in untreated SBP 120 mm Hg. Excess, observed in stratum−expected in stratum).”
Influential
Cited by
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000065 · Cited by 7,391
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000678 · Cited by 4,536
Self-citation(2019) · doi:10.1161/cir.0000000000000677 · Cited by 4,501
Self-citation2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.010 · Cited by 1,896
Self-citation
Metadata
- Authors
- Karmali, K. N., & Lloyd-Jones, D. M.
- Venue
- Hypertension
- Published
- 2017-03
- Volume
- 69
- Issue
- 3
- Pages
- e2-e9
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2581073278
- Cited by
- 55
- References
- 12
- FWCI
- 4.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Global Risk Assessment to Guide Blood Pressure Management in Cardiovascular Disease Prevention. https://app.cochat.ai/papers/10.1161/hypertensionaha.116.08249
- The paper
- Karmali, K. N., & Lloyd-Jones, D. M. (2017). Global Risk Assessment to Guide Blood Pressure Management in Cardiovascular Disease Prevention. Hypertension. https://doi.org/10.1161/hypertensionaha.116.08249
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.